Effect of Diabeat on type 2 diabetes mellitus

Anti-diabetic Potential of Diabeat in T2DM: A Preclinical and Clinical Evaluation

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/04/024477

Enrollment

Registered

2020-04-03

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Diabeat: A Poly-herbal Unani Formulation 1000 mg twice daily Control Intervention1: Metformin: Standard Control 500 mg twice daily

Eligibility

Inclusion criteria

Inclusion criteria: Patients with Type 2 Diabetes mellitus Age â?? 18 years and above Sex â?? Male / Female HbA1c >6.5%-8.5%

Exclusion criteria

Exclusion criteria: All mentally challenged and unconscious patients Diabetes mellitus with other complications Clinically relevant, Gastrointestinal, Hepatic, Renal, Neurological, Haematological or other major systemic disease Pregnant or Lactating women History of alcohol abuse

Design outcomes

Primary

Measure	Time frame
Change in HbA1c from the baselineTimepoint: 3 Months	—

Secondary

Measure	Time frame
Change in liver function test, kidney function test and lipid profile from the baselineTimepoint: 3 Months	—

Countries

India

Contacts

Public ContactYasmeen Shamsi

Jamia Hamdard

yshamsi@jamiahamdard.ac.in8750040776

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026